Autologous and allogeneic mesenchymal stem cell-based therapies for diabetes mellitus: A systematic review and meta-analysis

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Systematic review evaluates efficacy of mesenchymal stem cell therapies in diabetes, suggesting improved glycemic control and safety.

MSC-based therapies significantly improved glycemic control and reduced insulin requirements in diabetes patients.
β-cell function enhancement was observed, indicating potential for long-term diabetes management.
Systematic review analyzed clinical and preclinical trials from 2000 to 2025 on autologous and allogeneic MSC therapies.
Safety profiles showed minimal adverse effects with no fatal events reported, highlighting therapeutic promise.

Aringazina et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark